Best Oncology Companies in New Jersey, United States
The 77 best Oncology companies in New Jersey, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Celularity.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in New Jersey
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Celularity Developer of allogeneic cell therapies to treat multiple diseases 67Funding top 18%Patents top 30%Fin. health top 38%Moat top 38% All 11 signals ▾Fundingtop 18% Patentstop 30% Fin. healthtop 38% Moattop 38% Innovationtop 39% Growthtop 39% Newstop 39% Markettop 40% Techtop 48% Talentbottom 49% Globalbottom 40% Funding: Raised $290M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) Patents: 488 patents matched (strict assignee match) · 135 filings since 2022 vs 309 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $290M | 6 mo ago | 225 225 → 145 (-36%) | 2016 | Robert Hariri Chairman & CEO | 488 patents Placenta-derived cell and matrix therapies for regenerative, immuno, and anti‑aging applications | — |
| 2 | PMV Pharma Restoring mutated p53 function to treat cancer with precision oncology | $236M | 70 mo ago | 63 63 → 68 (+8%) | 2013 | Thomas Shenk Co-Founder | — | — |
| 3 | Tengion Regenerative medicine company developing neo-organs & neo-tissues. | $146M | 154 mo ago | 40 | 2004 | — | 77 patents Regenerative medicine scaffolds and cell therapies for organ augmentation and reconstruction | — |
| 4 | Advaxis Developer of immunotherapies for the treatment of cancer | $141M | 62 mo ago | 12 | 2002 | Ken Berlin President | 393 patents Engineered Listeria bacterial vectors for peptide vaccine delivery and lyophilized formulations. | — |
| 5 | Celator Pharma Celator Pharmaceuticals - Improving Patient Outcomes in Cancer | $137M | 157 mo ago | 20 | 1999 | Scott Jackson CEO | — | — |
| 6 | Convergent Therapeutics Developer of therapeutics to treat cancer | $130M | 22 mo ago | 4 | 2020 | Philip Kantoff Co-Founder & CEO | — | 1 partnership |
| 7 | Sopherion Therapeutics Limited information available | $128M | 208 mo ago | 11 | 2000 | — | — | — |
| 8 | Hengrui Therapeutics Developer of small molecule based therapeutics for the treatment of cancer, metabolic, and autoimmune… | $100M | 120 mo ago | 12 | 2016 | — | — | — |
| 9 | Immunomedics Developer of antibodies and antibody-drug conjugates for the treatment of cancer and autoimmune diseases | $95M | 101 mo ago | 358 | 1982 | — | 1,555 patents Antibody‑drug conjugates delivering SN‑38 for targeted cancer therapy and companion diagnostics | — |
| 10 | Ceptur Therapeutics Developer of oligonucleotide therapeutics for the treatment of cancer | $75M | 53 mo ago | 6 | 2021 | Samuel Gunderson Co-Founder | — | — |
| 11 | Interpace Biosciences Provider of molecular diagnostic tests and pathology services for cancer diagnosis | $72M | 20 mo ago | 94 | 1986 | Thomas Burnell CEO & President | — | — |
| 12 | Vyome Therapeutics Developer of therapeutics for the immuno-inflammatory conditions | $63M | 89 mo ago | 8 | 2010 | Venkateswarlu Nelabhotla Co-Founder & CEO | — | — |
| 13 | Cellectar Biosciences Developer of phospholipid drug conjugates (PDC) to treat cancer | $57M | 16 mo ago | 15 15 → 20 (+33%) | 2002 | — | 128 patents Targeted cancer therapy using phospholipid‑flavagline conjugates and dosing of ether analogs | — |
| 14 | Cyclacel Diversified company in fire protection and biopharmaceutical industries | $47M | 12 mo ago | 12 | 1996 | — | 8 patents Optimizing nucleoside analog anti‑cancer agents (sapacitabine) and their dosing regimens. | — |
| 15 | Cornerstone Pharmaceuticals Small molecule therapeutics targeting metabolic pathways to treat cancer | $44M | 115 mo ago | 17 | 2000 | Robert Shorr Co-Founder & Co-CEO | — | — |
| 16 | Rafael Pharma US-based, Clinical-stage biopharma exploiting cancer cells' Altered Energy Metabolism for drug development | $32M | 115 mo ago | 27 | 1999 | Sanjeev Luther CEO | — | — |
| 17 | Arno Therapeutics Invest 401k in physical gold, retirement planning, and financial advice | $30M | 117 mo ago | 7 | 2005 | — | — | — |
| 18 | Interpace Diagnostics Molecular diagnostics and pathology services for early cancer diagnosis and treatment | $27M | 83 mo ago | 120 | 2013 | — | — | — |
| 19 | Senesco Technologies Developer of antibodies against autoimmune disorders and metastatic tumors | $27M | 131 mo ago | 89 | 1998 | — | 226 patents Nucleic-acid therapeutics for cancer/apoptosis and agricultural biotech for yield improvement | — |
| 20 | DiamiR Developer of minimally invasive diagnostic tests | $22M | 13 mo ago | 13 | 2009 | — | 55 patents miRNA biomarker assays for diagnosing and monitoring Parkinson's and other neurodegenerative diseases | — |
| 21 | Gennao Bio Developer of nucleic acid therapeutics for cancer and rare muscular disorders | $16M | 42 mo ago | 37 | 2020 | Peter Glazer Co-Founder | — | — |
| 22 | Lisata Developer of therapeutics for cancer and vascular disorders | $15M | 71 mo ago | 27 | 2006 | — | — | — |
| 23 | Kayothera Developer of enzyme therapy for cancer treatment | $14M | 15 mo ago | 2 | 2018 | Mark Esposito Founder & CSO | 23 patents Design of heterocyclic aldehyde dehydrogenase inhibitor compounds for therapeutic use. | — |
| 24 | Immetas Developer of therapeutic solutions for treating cancers and inflammatory diseases | $11M | 69 mo ago | — | 2018 | J Wang Founder & CEO | — | — |
| 25 | Cancer Genetics Developer of cancer diagnostic solutions for personalized treatment | $10M | 65 mo ago | 110 | 1999 | John Roberts CEO | 35 patents Molecular diagnostic panels for cancer genomics and prognostic biomarker detection. | — |
| 26 | Enterix Easy at-home colorectal cancer screening using toilet bowl water | $8M | 298 mo ago | 54 | 1997 | Robert Max Mawhinney Co-Founder | 12 patents Rapid point-of-care analyte detection and sample collection devices | — |
| 27 | SilaGene Early-stage cancer therapeutics discovery company developing gene silencing technologies | $6M | 70 mo ago | — | 2008 | Samuel Gunderson Co-Founder & President | 23 patents Therapeutics targeting neurodegenerative diseases, especially Huntington's disease, via novel compounds. | — |
| 28 | Teclison Developer immunotherapies for the treatment of cancer | $6M | 52 mo ago | 6 | 2013 | Ray Lee Founder | 11 patents Patents concentrated in health & consumer products | — |
| 29 | Adgero Biopharma Developer of photodynamic therapy for cutaneous metastatic breast cancer | $6M | 71 mo ago | 7 | 2012 | — | — | — |
| 30 | Atux Iskay Developer of small molecule modulators of Protein Phosphatase 2A | $5M | 15 mo ago | — | 2018 | Michael Ohlmeyer Founder | 20 patents Medicinal chemistry of diaryl‑substituted tetrahydropyran and methylene scaffolds for therapeutic agents | — |
| 31 | Hepion Pharmaceuticals Provides therapeutics for chronic liver disorder | $5M | 32 mo ago | 17 | 2013 | — | — | — |
| 32 | Avotres Provider of transformational therapies for autoimmune diseases, cancers, and transplantation | $4M | 63 mo ago | 5 | 2017 | Sean Hu CEO | 12 patents Peptide‑loaded dendritic cell immunotherapies for autoimmune disease treatment | — |
| 33 | CytoSite Bio Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $3M | 68 mo ago | — | 2016 | Benjamin Larimer Co-Founder | — | — |
| 34 | Vuja De Sciences Developer of therapies for preventing metastasis and recurrence of cancers | $3M | 20 mo ago | 7 | 2017 | — | — | — |
| 35 | TDL Innovations Developer of device to treat malignant pleural effusion | $2M | 60 mo ago | — | 2014 | Glenn Laub Co-Founder & CEO | 43 patents Minimally invasive therapeutic foams and steerable catheter systems for drug delivery and tissue sampling | — |
| 36 | Sentrimed Developer of precision oncology therapeutics | $2M | 1 mo ago | — | 2011 | Bill Ragatz President and CEO | 2 patents Patents concentrated in health & consumer products | — |
| 37 | Vicus Therapeutics Mid-clinical stage immunotherapy company developing immune modulators for Liver and Pancreatic Cancer | $1M | 190 mo ago | 5 | 2005 | John Maki CEO & President | — | — |
| 38 | Oncospire Genomics Developer of NGS gene panels for oncology | $1M | 156 mo ago | 86 | 2013 | Panna Sharma CEO & President | — | — |
| 39 | Sonnet BioTherapeutics Developer of immunotherapies for the treatment of cancer | $750K | 18 mo ago | 12 12 → 11 (-8%) | 2011 | Pankaj Mohan Founder & CEO & Chairman
| 46 patents Engineered cytokine‑albumin fusion proteins for enhanced therapeutic biologics | — |
| 40 | PDS Biotechnology Developer of immunostimulatory nanoparticle vaccine for cancer and infectious diseases | $750K | 45 mo ago | 26 26 → 33 (+27%) | 2005 | Frank Bedu-Addo President and CEO | 148 patents Non‑HLA‑restricted T‑cell vaccine platforms and cationic lipid delivery for cancer immunotherapy | — |
| 41 | GeneAssess Provider of diagnostic and genetic tests for assessing cancer risk based on a biomarker | $500K | 167 mo ago | — | 2012 | Helmut Zarbl CEO | — | — |
| 42 | Bound Therapeutics Pioneering RNA cancer therapy using AI for targeted drug delivery | $300K | 84 mo ago | 6 | 2015 | Yuanyuan Jin Co-Founder & COO | — | — |
| 43 | XEME Biopharma Inc. Developer of active cancer immunotherapy products focused on personalized cancer vaccines | $167K | 213 mo ago | 4 | 2005 | — | — | — |
Top 12 Oncology companies in New Jersey
#1
Public · Warren, New Jersey · founded 2016 · 225 employees$290Mraised▾
Developer of allogeneic cell therapies to treat multiple diseases. The company focuses on placenta-derived cell therapy product candidates for cancer, infectious diseases, and degenerative diseases. The company's lead candidate is CYNK001 for acute myeloid leukemia and Glioblastoma.
- Dec 2025Post IPO$10M
- Oct 2025Post IPO$2M
- Jul 2025Post IPO$2M
- Jul 2025Post IPO$1M
#2
Public · Berkeley Heights, New Jersey · founded 1996 · 12 employees$47.3Mraised▾
Diversified company in fire protection and biopharmaceutical industries. It operates in two distinct sectors: fire safety and biopharmaceuticals. The fire safety division supplies protective equipment to domestic and international markets, offering a range of products including fire equipment, foam systems, fire-resistant doors, and personal protective equipment. The biopharmaceutical division focuses on developing innovative cancer medicines based on cell cycle, epigenetics, and mitosis biology, aiming to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and increase overall survival. The company fosters a culture of growth and adaptive thinking, exploring new possibilities and driving positive value for all stakeholders.
- Jun 2025Post IPO$3M
- Mar 2025Post IPO$1M
- Nov 2024Post IPO$2.1M
- May 2024Post IPO$8M
#3
Seed · Mullica Hill, New Jersey · founded 2011$2Mraised▾
Developer of precision oncology therapeutics. The company develops targeted therapies that exploit cell-to-cell communications essential to recognizing cancer. The product pipeline include MASL an orally dosed, bioactive lectin that inhibits PDPN and blocks PDPN mediated activation of Cdc42 and downstream signaling important to cancer progression.
- May 2026Seed$250K
- Feb 2025Grant (prize money)$604.1K
- Feb 2024Seed$500K
- Nov 2023Grant (prize money)$604.1K
#4
Acquired · Florham Park, New Jersey · founded 2002 · 15 employees$57Mraised▾
Developer of phospholipid drug conjugates (PDC) to treat cancer. The company's lead therapeutic PDC includes CLR 131 that utilizes a cytotoxic radioisotope iodine-131 works by damaging DNA of cancer cell. The company's other product includes CLR 131 used to treat solid tumours that work by arresting cell cycle in cancer cells. The company also aims to develop PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX). It has developed its proprietary phospholipid ether (PLE) delivery platform which is coupled with drugs using a linker to facilitate targeted delivery of drugs to the cancer cell.
- Jan 2025Grant (prize money)$1.7M
- Sep 2023Post IPO$24.5M
- Sep 2022Grant (prize money)$1.6M
- Sep 2021Grant (prize money)$1.7M
#5
Funding Raised · Monmouth Junction, New Jersey · founded 2009 · 13 employees$21.8Mraised▾
Developer of minimally invasive diagnostic tests. It has developed a proprietary targeted approach for early detection and monitoring of neurodegenerative diseases based on quantitative analysis of brain-enriched microRNA pairs in plasma. The company has collaborated with Janssen Neuroscience to investigate how DiamiR technology can be used in the context of clinical development of a therapeutic agent for the treatment of neurodegenerative disease. Its lead product CogniMir is aimed at early detection of circulating miRNAs for the early detection of Alzheimer's disease.
- May 2025Grant (prize money)$9.5M
- Sep 2020Grant (prize money)$609.5K
- Sep 2019Grant (prize money)$345K
- Jun 2016Grant (prize money)$224.6K
#6
Series A · New Jersey · founded 2020 · 4 employees$130Mraised▾
Developer of therapeutics to treat cancer. The company uses a proprietary technology that involves dual-targeted radionuclide therapy (RNT) to design CONV01-α, a monoclonal antibody conjugated with actinium-225 (225Ac), to direct a radioisotope to prostate cancer.
- Jul 2024Series A$40M
- Apr 2023Series A$90M
#7
Public · Parsippany Troy Hills, New Jersey · founded 1986 · 94 employees$72.1Mraised▾
Provider of molecular diagnostic tests and pathology services for cancer diagnosis. It offers molecular analysis for early cancer diagnosis and treatment. The company provides clinically beneficial, evidence-based molecular diagnostic tests and pathology services.
- Oct 2024Post IPO$47M
- Jan 2020Post IPO$20M
- Oct 2017Post IPO$5M
- Jan 2017Post IPO$111.2K
#8
Series A · Princeton, New Jersey · founded 2018 · 2 employees$14Mraised▾
Developer of enzyme therapy for cancer treatment. The platform is developing technology that can inhibit the enzyme that is responsible for protecting the cancer cell. The platform uses two pathways that are inhibition of the cancer stress resistance pathway and the other is depletion of regulatory T cells.
- Mar 2025Grant (prize money)$398K
- Jul 2023Grant (prize money)—
- Jul 2023Series A$5.2M
- May 2023Grant (prize money)$337.6K
#9
Funding Raised · Princeton, New Jersey · founded 2018$5.3Mraised▾
Developer of small molecule modulators of Protein Phosphatase 2A (PP2A). The company focuses on therapeutic areas including oncology, neurodegenerative disease, and respiratory disease. Its PP2A activators have senotherapeutic potential and are being developed to impact human health. It provides samples of PP2A activator compounds to academic researchers to foster collaborations and publications, particularly seeking researchers in aging and metabolic disease/diabetes.
- Mar 2025Grant (prize money)$2.5M
- Jun 2022Grant (prize money)$406.5K
- Sep 2020Grant (prize money)$2.1M
- Jul 2020Grant (prize money)$199.6K
#10
Seed · Hoboken, New Jersey · founded 2017 · 7 employees$2.7Mraised▾
Developer of therapies for preventing metastasis and recurrence of cancers. It offers a lead candidate VUJ-100 that has anti metastatic activity based on properitory platform for multiple metastatic osteosarcoma and other cancer models.
- Oct 2024Conventional Debt—
- Oct 2024Seed$370K
- Feb 2024Seed$700K
- Feb 2024Conventional Debt—
#11
Public · Cranbury, New Jersey · founded 2013 · 63 employees$236Mraised▾
Restoring mutated p53 function to treat cancer with precision oncology. The company is dedicated to developing unique therapies by selectively targeting mutant p53 proteins, addressing a critical area in cancer treatment. They focus on structurally correcting the geometry of the p53 protein to restore its tumor-suppressing function. This innovative approach aims to provide personalized treatment options for patients whose tumors harbor p53 gene mutations. Their research and development efforts are centered around precision oncology, leveraging insights into the p53 protein to create targeted therapeutics. The company's work has potential social impact by offering new hope for cancer patients with limited treatment options.
- Aug 2020Series D$70M
- Nov 2019Series C$62M
- Mar 2017Series B$74M
- Dec 2014Series A$30M
#12
Acqui-Hired · Princeton, New Jersey · founded 2002 · 12 employees$140.7Mraised▾
Developer of immunotherapies for the treatment of cancer. The company uses its proprietary platform for the development of cancer therapy that redirects the immune system to kill cancer. It uses bioengineered live attenuated bacteria, Listeria monocytogenes (Lm) which suppresses the growth of tumor microenvironment.
- Apr 2021Post IPO—
- Aug 2020Post IPO—
- Jan 2020Post IPO$10.5M
- Aug 2015Post IPO$25M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in the United States
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 12,968 United States-affiliated papers.
- Harvard University573
- The University of Texas MD Anderson Cancer Center559
- Dana-Farber Cancer Institute413
- Johns Hopkins University356
- Cornell University352
- Tumor microenvironment124→1921
- Immune system80→1464
- Immunotherapy66→1342
- Cancer research197→1345
- Cancer immunotherapy35→714
- Tumor microenvironment212→2712
- Immune system142→2161
- Immunotherapy146→1778
- Cancer research238→1815
- Cancer immunotherapy73→718
- Immunotherapy42→624
- Tumor microenvironment65→585
- Immune system31→529
- Cancer immunotherapy27→298
- Cancer research49→277
Where oncology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing oncology patents in the United States
United States oncology patent filing is accelerating — 2,574 filings from 797 assignees (2016–2025), led by Bristol Myers Squibb, IO Therapeutics, UNIV California; annual filings 108→277.
- Bristol Myers Squibb105
- IO Therapeutics91
- UNIV California88
- DANA Farber Cancer INST87
- Memorial Sloan Kettering Cancer 74
- Baylor College Medicine63
- UNIV Texas61
- Massachusetts INST Technology47
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.